These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 31211843)

  • 21. Cell-type-specific miR-431 dysregulation in a motor neuron model of spinal muscular atrophy.
    Wertz MH; Winden K; Neveu P; Ng SY; Ercan E; Sahin M
    Hum Mol Genet; 2016 Jun; 25(11):2168-2181. PubMed ID: 27005422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A large animal model of spinal muscular atrophy and correction of phenotype.
    Duque SI; Arnold WD; Odermatt P; Li X; Porensky PN; Schmelzer L; Meyer K; Kolb SJ; Schümperli D; Kaspar BK; Burghes AH
    Ann Neurol; 2015 Mar; 77(3):399-414. PubMed ID: 25516063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Perturbed MicroRNA Expression Pattern Characterizes Embryonic Neural Stem Cells Derived from a Severe Mouse Model of Spinal Muscular Atrophy (SMA).
    Luchetti A; Ciafrè SA; Murdocca M; Malgieri A; Masotti A; Sanchez M; Farace MG; Novelli G; Sangiuolo F
    Int J Mol Sci; 2015 Aug; 16(8):18312-27. PubMed ID: 26258776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of genetic background on the phenotype of the Smn2B/- mouse model of spinal muscular atrophy.
    Eshraghi M; McFall E; Gibeault S; Kothary R
    Hum Mol Genet; 2016 Oct; 25(20):4494-4506. PubMed ID: 28172892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurocalcin Delta Suppression Protects against Spinal Muscular Atrophy in Humans and across Species by Restoring Impaired Endocytosis.
    Riessland M; Kaczmarek A; Schneider S; Swoboda KJ; Löhr H; Bradler C; Grysko V; Dimitriadi M; Hosseinibarkooie S; Torres-Benito L; Peters M; Upadhyay A; Biglari N; Kröber S; Hölker I; Garbes L; Gilissen C; Hoischen A; Nürnberg G; Nürnberg P; Walter M; Rigo F; Bennett CF; Kye MJ; Hart AC; Hammerschmidt M; Kloppenburg P; Wirth B
    Am J Hum Genet; 2017 Feb; 100(2):297-315. PubMed ID: 28132687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset.
    Feng Z; Ling KK; Zhao X; Zhou C; Karp G; Welch EM; Naryshkin N; Ratni H; Chen KS; Metzger F; Paushkin S; Weetall M; Ko CP
    Hum Mol Genet; 2016 Mar; 25(5):964-75. PubMed ID: 26758873
    [TBL] [Abstract][Full Text] [Related]  

  • 27. miR-206 Reduces the Severity of Motor Neuron Degeneration in the Facial Nuclei of the Brainstem in a Mouse Model of SMA.
    Valsecchi V; Anzilotti S; Serani A; Laudati G; Brancaccio P; Guida N; Cuomo O; Pignataro G; Annunziato L
    Mol Ther; 2020 Apr; 28(4):1154-1166. PubMed ID: 32075715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct central nervous system delivery provides enhanced protection following vector mediated gene replacement in a severe model of spinal muscular atrophy.
    Glascock JJ; Shababi M; Wetz MJ; Krogman MM; Lorson CL
    Biochem Biophys Res Commun; 2012 Jan; 417(1):376-81. PubMed ID: 22172949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Decreasing disease severity in symptomatic, Smn(-/-);SMN2(+/+), spinal muscular atrophy mice following scAAV9-SMN delivery.
    Glascock JJ; Osman EY; Wetz MJ; Krogman MM; Shababi M; Lorson CL
    Hum Gene Ther; 2012 Mar; 23(3):330-5. PubMed ID: 22029744
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Central and peripheral delivered AAV9-SMN are both efficient but target different pathomechanisms in a mouse model of spinal muscular atrophy.
    Reilly A; Deguise MO; Beauvais A; Yaworski R; Thebault S; Tessier DR; Tabard-Cossa V; Hensel N; Schneider BL; Kothary R
    Gene Ther; 2022 Sep; 29(9):544-554. PubMed ID: 35462564
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromuscular denervation and deafferentation but not motor neuron death are disease features in the Smn2B/- mouse model of SMA.
    Carlini MJ; Triplett MK; Pellizzoni L
    PLoS One; 2022; 17(8):e0267990. PubMed ID: 35913953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy.
    Ahmad S; Wang Y; Shaik GM; Burghes AH; Gangwani L
    Hum Mol Genet; 2012 Jun; 21(12):2745-58. PubMed ID: 22422766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitigating aberrant Cdk5 activation alleviates mitochondrial defects and motor neuron disease symptoms in spinal muscular atrophy.
    Miller N; Xu Z; Quinlan KA; Ji A; McGivern JV; Feng Z; Shi H; Ko CP; Tsai LH; Heckman CJ; Ebert AD; Ma YC
    Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2300308120. PubMed ID: 37976261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN.
    Foust KD; Wang X; McGovern VL; Braun L; Bevan AK; Haidet AM; Le TT; Morales PR; Rich MM; Burghes AH; Kaspar BK
    Nat Biotechnol; 2010 Mar; 28(3):271-4. PubMed ID: 20190738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glial Activation and Central Synapse Loss, but Not Motoneuron Degeneration, Are Prevented by the Sigma-1 Receptor Agonist PRE-084 in the Smn2B/- Mouse Model of Spinal Muscular Atrophy.
    Cerveró C; Blasco A; Tarabal O; Casanovas A; Piedrafita L; Navarro X; Esquerda JE; Calderó J
    J Neuropathol Exp Neurol; 2018 Jul; 77(7):577-597. PubMed ID: 29767748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
    Kannan A; Jiang X; He L; Ahmad S; Gangwani L
    Brain; 2020 Jan; 143(1):69-93. PubMed ID: 31828288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. miRNA malfunction causes spinal motor neuron disease.
    Haramati S; Chapnik E; Sztainberg Y; Eilam R; Zwang R; Gershoni N; McGlinn E; Heiser PW; Wills AM; Wirguin I; Rubin LL; Misawa H; Tabin CJ; Brown R; Chen A; Hornstein E
    Proc Natl Acad Sci U S A; 2010 Jul; 107(29):13111-6. PubMed ID: 20616011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E; Mendoza-Ferreira N; Hosseinibarkooie S; Schneider S; Hupperich K; Tschanz T; Grysko V; Riessland M; Hammerschmidt M; Rigo F; Bennett CF; Kye MJ; Torres-Benito L; Wirth B
    Brain; 2018 Aug; 141(8):2343-2361. PubMed ID: 29961886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced survival of motor neuron (SMN) protein in motor neuronal progenitors functions cell autonomously to cause spinal muscular atrophy in model mice expressing the human centromeric (SMN2) gene.
    Park GH; Maeno-Hikichi Y; Awano T; Landmesser LT; Monani UR
    J Neurosci; 2010 Sep; 30(36):12005-19. PubMed ID: 20826664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term peripheral AAV9-SMN gene therapy promotes survival in a mouse model of spinal muscular atrophy.
    Reilly A; Yaworski R; Beauvais A; Schneider BL; Kothary R
    Hum Mol Genet; 2024 Feb; 33(6):510-519. PubMed ID: 38073249
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.